A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emphasizing the need for early multidisciplinary coordination to address ...

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

John Burke, MD, discusses his editor-in-chief column from the July 2025 issue of Targeted Therapies in Oncology.

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and ...

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...

Benjamin Schlechter, MD, discusses the safety and efficacy findings from the C-800-01 phase 1 trial evaluating botensilimab ...

Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated ...

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, ...